

略歴、主な業績

2023年3月6日

【氏名】 井上 義一 (いのうえよしかず)

【現職】 国立病院機構近畿中央呼吸器センター
臨床研究センター長
難治性肺疾患研究部長（併任）
結核ワクチン治療研究室長（併任）

大阪大学大学院医学系研究科腫瘍感染免疫学講座 招へい教授

【経歴】

- 1983年3月 愛媛大学医学部卒業
1983年4月 愛媛大学医学部附属病院研修医（第二内科）
1984年4月 愛媛大学医学部医学研究科博士課程(大学院)入学
1988年3月 愛媛大学医学部医学研究科博士課程修了（医学博士）
1988-1991年 国立療養所愛媛病院呼吸器科医師
1991年4月 愛媛大学医学部付属病院助手（第二内科）
1994-1997年 米国留学（National Jewish Center for Immunology and Respiratory Medicine, University of Colorado, Health Science Center, USA）(1994-1997)
1997年 国立療養所近畿中央病院内科医長
1998年 国立療養所近畿中央病院 臨床研究部免疫研究室室長（内科医長兼任）
2001年 国立療養所近畿中央病院 臨床研究センター呼吸不全研究部長
2004年 国立病院機構近畿中央胸部疾患センター 臨床研究センター呼吸不全難治性肺疾患研究部長
2006年 大阪大学医学系研究科連携大学院 肿瘍感染免疫学 担任教授
2011年から 大阪大学大学院医学系研究科連携大学院腫瘍感染免疫学招聘教授（現職）
2014年から 国立病院機構近畿中央胸部疾患センター、臨床研究センター長
2018年から 国立病院機構呼吸器ネットワークグループリーダー（現職）
2018年から 国立病院機構近畿中央呼吸器センター（改名）臨床研究センター長（現職）

【主な学会役員等】

- 2008年から 日本サルコイドーシス肉芽腫性疾患学会理事（現）
2008-2014年 APSR, Assembly Head of Interstitial Lung Disease
2009-2011年 日本呼吸器学会びまん性肺疾患学術部会会長
2010-2013年 ATS/ERS International Multidisciplinary Classification of Idiopathic Interstitial Pneumonias
2011年から 日本呼吸器内視鏡学会評議員（現）
2011-2017年 WASOG, Executive Committee, Member
2013年-2022 日本呼吸器学会代議員
2014年から 日本肺サーファクタント・界面医学会理事（現）
2015年 日本肺サーファクタント・界面医学会会長

2015-2017 年	日本呼吸器学会特発性間質性肺炎診断と治療の手引き作成委員会委員
2015-2017 年	日本呼吸器学会特発性肺線維症治療ガイドライン委員
2017-2017 年	日本呼吸器学会特発性間質性肺炎合併肺癌ガイドライン委員
2016-2017 年	ATS/JRS LAM 診療ガイドライン委員
2017-2018 年	ATS/ERS/JRS/ALAT IPF 診療ガイドライン委員
2018 年	Fleishner Society President-Elect
2019 年から	ATS/JRS/ALAT HP, ATS/ERS/JRS/CPFE 診療ガイドライン委員
2019 年から	JRS 肺胞蛋白症診療ガイドライン委員長
2019 年	Fleishner Society, 会長
2019-2020 年	ATS/ERS/JRS/ALAT 過敏性肺炎、CPFE 診療ガイドライン委員
2020-2022 年	ATS/JRS/ALAT IPF, PPF 診療ガイドライン委員
2021 年	Fleishner Society, 理事/前会長
2021 年	日本サルコイドーシス肉芽腫性疾患学会会長、理事、支部長

【専門医等、資格】(2022 年 10 月現在)

日本呼吸器学会（専門医 1991 年～、指導医 2004 年～）
 日本循環器学会（専門医 1994 年～）
 日本呼吸器内視鏡学会（気管支鏡専門医、指導医 1990 年～）
 日本結核病学会（現日本結核・非結核性抗酸菌症学会）（認定医 2012 年～、指導医 2017 年～）
 日本内科学会（認定内科医 1989 年～）、

【主な公的研究班分担等（2019 年以降）】

1. 日本医療研究開発機構(2019-2021 年大阪大学)、横断的オミクス解析を駆使した肺胞蛋白症の病態解明とインシリコ・リポジショニング創薬（岡田随象）、分担、
2. 日本医療研究開発機構、難治性疾患実用化研究事業（2017-2019 年、近畿中央呼吸器センター）、肺胞蛋白症診療に直結するエビデンス創出研究：重症難治例の診断治療管理（井上義一）、代表
3. 日本医療研究開発機構（2016-2020、近畿中央呼吸器センター）、多剤耐性結核に対する新規治療用 DNA ワクチンの開発・実用化に向けた研究（岡田全司）、分担
4. 文部科学省、基盤研究（C）（2019-2021 年、近畿中央呼吸器センター）、特発性間質性肺炎急性増悪の新規バイオマーカーの開発（新井徹）、分担
5. 文部科学省、基盤研究（C）（2019-2021 年、近畿中央呼吸器センター）、細胞外小胞に着目した包括的アプローチによるリンパ脈管筋腫症のバイオマーカー開発（滝本宜之）、分担
6. 厚生労働省、難治性疾患等政策研究事業（2020-2022 年、浜松医科大学）びまん性肺疾患に関する調査研究（須田隆文）、分担
7. 厚生労働省、難治性疾患等政策研究事業（2020-2022 年、獨協医科大学）、特発性造血障害に関する調査研究（三谷絹子）、分担
8. 厚生労働省、難治性疾患等政策研究事業（2020-1022、京都大学）、難治性呼吸器疾患・肺高血圧症に関する調査研究（平井豊博）、分担

【表彰等】

2010 年から	The Best Doctors in Japan
2015 年	Scientific Advancement Award 受賞, The LAM Foundation (Chicago)

【社会活動、患者支援等】

2001 年から	J-LAM の会（日本 LAM 患者会）医療アドバイザー（現）
2004 年から	The Pulmonary Alveolar Proteinosis Foundation Clinical Advisory Board（現）
2007-2014 年	The LAM Foundation (米国 LAM 患者会) Clinical Science Board
2010 年から	日本肺胞蛋白症患者会 顧問（現）
2014 年から	The LAM Foundation (米国 LAM 患者会) Scientific Advisory Board（現）
2014 年から	The LAM Foundation International LAM Clinic, Clinical director（現）

【主要英文論文(2023年3月6日まで)】 English publications, (+ More than 200 Japanese Publications)

1. Uehara Y, Tanaka Y, Zhao S, Nikolaidis NM, Pitstick LB, Wu H, Yu JJ, Zhang E, Hasegawa Y, Noel JG, Gardner JC, Kopras EJ, Haffey WD, Greis KD, Guo J, Woods JC, Wikenheiser-Brokamp KA, Kyle JE, Ansong C, Teitelbaum SL, **Inoue Y**, Altinişik G, Xu Y, McCormack FX. Insights into pulmonary phosphate homeostasis and osteoclastogenesis emerge from the study of pulmonary alveolar microlithiasis. *Nat Commun.* 2023 Mar 2;14(1):1205. doi: 10.1038/s41467-023-36810-8.
2. Ogura T, **Inoue Y**, Azuma A, Homma S, Kondoh Y, Tanaka K, Ochiai K, Sugiyama Y, Nukiwa T. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan. *Adv Ther.* 2023 Jan 24. doi: 10.1007/s12325-022-02411-y. Online ahead of print.
3. Osaki M, Arai T, Sumikawa H, Takimoto T, Takeuchi N, Tamiya A, Okishio K, **Inoue Y**. Immune checkpoint inhibitor-related pneumonitis in lung cancer patients with interstitial lung disease: Significance of radiological pleuroparenchymal fibroelastosis. *Oncology.* 2023 Jan 23. doi: 10.1159/000529204. Online ahead of print.
4. Suzukawa M, Ohta K, Hashimoto H, Oyamada Y, Miki M, Ogawara M, **Inoue Y**, Saito AM, Fukutomi Y, Kobayashi N, Taniguchi M; NHOM-Asthma study group. Characterization and cluster analyses of elderly asthma in comparison with non-elderly asthma patients in Japan. *Ann Allergy Asthma Immunol.* 2023 Jan 16;S1081-1206(23)00005-4.
5. **Inoue Y**, Wells AU, Song JW, Xu Z, Kitamura H, Suda T, Okamoto M, Müller H, Coeck C, Rohr KB, Kolb M, Brown KK. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. *Respirology.* 2023 Jan 15. doi: 10.1111/resp.14452. Online ahead of print.
6. Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, Corte TJ, Dickinson JL, Glaspole I, Moodley YP, Vasakova MK, Bendstrup E, Davidsen JR, Borie R, Crestani B, Dieude P, Bonella F, Costabel U, Gudmundsson G, Donnelly SC, Egan J, Henry MT, Keane MP, Kennedy MP, McCarthy C, McElroy AN, Olaniyi JA, O'Reilly KMA, Richeldi L, Leone PM, Poletti V, Puppo F, Tomassetti S, Luzzi V, Kokturk N, Mogulkoc N, Fiddler CA, Hirani N, Jenkins G, Maher TM, Molyneaux PL, Parfrey H, Braybrooke R, Blackwell TS, Jackson PD, Nathan SD, Porteous MK, Brown KK, Christie JD, Collard HR, Eickelberg O, Foster EE, Gibson KF, Glassberg M, Kass D, Kropski JA, Lederer D, Linderholm AL, Loyd J, Mathai SK, Montesi SB, Noth I, Oldham JM, Palmisciano AJ, Reichner CA, Rojas M, Roman J, Schluger N, Shea BS, Swigris JJ, Wolters PJ, Zhang Y, Prele CMA, Enghelmayer JI, Otaola M, Ryerson CJ, Salinas M, Sterclova M, Gebremariam TH, Myllärniemi M, Carbone R, Furusawa H, Hirose M, **Inoue Y**, Miyazaki Y, Ohta K, Ohta S, Okamoto T, Kim DS, Pardo A, Selman M, Aranda AU, Park MS, Park JS, Song JW, Molina-Molina M, Planas-Cerezales L, Westergren-Thorsson G, Smith AV, Manichaikul AW, Kim JS, Rich SS, Oelsner EC, Barr RG, Rotter JI, Dupuis J, O'Connor G, Vasan RS, Cho MH, Silverman EK, Schwarz MI, Steele MP, Lee JS, Yang IV, Fingerlin TE, Schwartz DA; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants. *Am J Respir Crit Care Med.* 2023 Jan 5. doi: 10.1164/rccm.202207-1331OC
7. Okuda R, Ogura T, Hisata S, Baba T, Kondoh Y, Suda T, Johkoh T, Iwasawa T, Tomioka H, Bando M, Azuma A, **Inoue Y**, Arai T, Nakamura Y, Miyamoto A, Miyazaki Y, Chiba H, Ishii H, Hamada N, Terasaki Y, Kuwahira I, Sato S, Kato S, Suzuki T, Sakamoto S, Nishioka Y, Hattori N, Hashimoto N, Morita S, Ichihara N,

- Miyata H, Hagiwara K, Nukiwa T, Kobayashi K. Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry. *Respir Investig*. 2022 Nov 15;S2212-5345(22)00142-3.
8. Takeuchi N, Arai T, Sasaki Y, Akira M, Matsuda Y, Tachibana K, Kasai T, **Inoue Y**. Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia. *J Thorac Dis*. 2022 Nov;14(11):4352-4360.
 9. Oda M, Yamaura K, Ishii H, Kitamura N, Tazawa R, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, **Inoue Y**, Arai T, Asakawa K, Tanaka T, Takada T, Nonaka H, Nakata K. Quantitative Evaluation of Changes in Three-Dimensional CT Density Distributions in Pulmonary Alveolar Proteinosis after GM-CSF Inhalation. *Respiration*. 2022 Dec 9:1-9. doi: 10.1159/000528038
 10. Akiyama N, Fujisawa T, Morita T, Koyauchi T, Matsuda Y, Mori M, Miyashita M, Tachikawa R, Tomii K, Tomioka H, Hagimoto S, Kondoh Y, **Inoue Y**, Suda T. End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation. *Respir Res*. 2022 Oct 29;23(1):294.
 11. Yamada A, Kagawa T, Nishimoto Y, Sugawara R, Arai T, **Inoue Y**, Taiji R, Okada H, Takewa M, Sugimura H, Tanaka T. Exogenous Lipoid Pneumonia Caused by Gargling With Sesame Oil: A Case Report. *J Thorac Imaging*. 2022 Nov 1;37(6):W97-W100.
 12. Nishioka Y, Toyoda Y, Egashira R, Johkoh T, Terasaki Y, Hebisawa A, Abe K, Baba T, Fujikura Y, Fujita E, Hamada N, Handa T, Hasegawa Y, Hidaka K, Hisada T, Hisata S, Honjo C, Ichikado K, **Inoue Y**, Izumi S, Kato M, Kishimoto T, Okamoto M, Miki K, Mineshita M, Nakamura Y, Sakamoto S, Sano M, Tsukada Y, Yamasue M, Bando Y, Homma S, Hagiwara K, Suda T, Inase N. Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype. *BMJ Open Respir Res*. 2022 Sep;9(1):e001337.
 13. Arai T, **Inoue Y**. Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist. *ERJ Open Res*. 2022 Sep 26;8(3):00242-2022.
 14. Yoshida S, Tsuyuguchi K, Kobayashi T, Shimatani Y, **Inoue Y**. Effect of sputum quality on Mycobacterium avium-intracellulare complex lung disease diagnosis and treatment initiation according to disease type. *Diagn Microbiol Infect Dis*. 2022 Nov;104(3):115773
 15. Cottin V, Selman M, **Inoue Y**, Wong AW, Corte TJ, Flaherty KR, Han MK, Jacob J, Johannson KA, Kitaichi M, Lee JS, Agusti A, Antoniou KM, Bianchi P, Caro F, Florenzano M, Galvin L, Iwasawa T, Martinez FJ, Morgan RL, Myers JL, Nicholson AG, Occhipinti M, Poletti V, Salisbury ML, Sin DD, Sverzellati N, Tonia T, Valenzuela C, Ryerson CJ, Wells AU. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. *Am J Respir Crit Care Med*. 2022 Aug 15;206(4):e7-e41. doi: 10.1164/rccm.202206-1041ST. PMID: 35969190
 16. Yoshida S, Tsuyuguchi K, Kobayashi T, Shimatani Y, **Inoue Y**. Effect of sputum quality on Mycobacterium avium-intracellulare complex lung disease diagnosis and treatment initiation according to disease type. *Diagn Microbiol Infect Dis*. 2022 Jul 22;104(3):115773. doi: 10.1016/j.diagmicrobio.2022.115773. Online ahead of print.
 17. Ogura T, Suda T, Inase N, Nishioka Y, Azuma A, Okamoto M, Takizawa A, Ito T, Rohr KB, **Inoue Y**. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. *Respir Investig*. 2022 Aug 1:S2212-5345(22)00090-9. doi: 10.1016/j.resinv.2022.06.009. Online ahead of print.

18. Moda M, Arai T, Takeuchi N, Kagawa T, Takimoto T, Sumikawa H, Shimizu S, **Inoue Y**. A Case of Fibrotic Hypersensitivity Pneumonitis Diagnosed by a Re-evaluation with Bronchoalveolar Lavage at Disease Deterioration. *Intern Med.* 2022 Jul 22. doi: 10.2169/internalmedicine.9736-22. Online ahead of print.
19. Suzukawa M, Ohta K, Fukutomi Y, Hashimoto H, Endo T, Abe M, Kamide Y, Yoshida M, Kikuchi Y, Kita T, Chibana K, Tanimoto Y, Hyodo K, Takata S, Inui T, Yasui M, Harada Y, Sato T, Sakakibara Y, Minakata Y, **Inoue Y**, Tamaki S, Shinohara T, Takami K, Tsubakihara M, Oki M, Wakamatsu K, Horiba M, Ideura G, Hidaka K, Saito AM, Kobayashi N, Taniguchi M. Classifications of moderate to severe asthma phenotypes in Japan and analysis of serum biomarkers: A Nationwide Cohort Study in Japan (NHOM Asthma Study). *Allergol Int.* 2022 Jul 2:S1323-8930(22)00071-5. doi: 10.1016/j.alit.2022.06.002. Online ahead of print.
20. Marinescu DC, Raghu G, Remy-Jardin M, Travis WD, Adegunsoye A, Beasley MB, Chung JH, Churg A, Cottin V, Egashira R, Fernández Pérez ER, **Inoue Y**, Johannson KA, Kazerooni EA, Khor YH, Lynch DA, Müller NL, Myers JL, Nicholson AG, Rajan S, Saito-Koyama R, Troy L, Walsh SLF, Wells AU, Wijsenbeek MS, Wright JL, Ryerson CJ. Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. *Chest.* 2022 Jun 20:S0012-3692(22)01102-3. doi: 10.1016/j.chest.2022.06.013. Online ahead of print.
21. Ganesh Raghu, Martine Remy-Jardin, Luca Richeldi, Carey C Thomson, **Yoshikazu Inoue**, Takeshi Johkoh, Michael Kreuter, David A Lynch, Toby M Maher, Fernando J Martinez, Maria Molina-Molina, Jeffrey L Myers, Andrew G Nicholson, Christopher J Ryerson, Mary E Strek, Lauren K Troy, Marlies Wijsenbeek, Manoj J Mammen, Tanzib Hossain, Brittany D Bissell, Derrick D Herman, Stephanie M Hon, Faye Kheir, Yet H Khor, Madalina Macrea, Katerina M Antoniou, Demosthenes Bouros, Ivette Buendia-Roldan, Fabian Caro, Bruno Crestani, Lawrence Ho, Julie Morisset, Amy L Olson, Anna Podolanczuk, Venerino Poletti, Moisés Selman, Thomas Ewing, Stephen Jones, Shandra L Knight, Marya Ghazipura, Kevin C Wilson. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST. PMID: 35486072
22. Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. *N Engl J Med.* 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. PMID: 35569036
23. Arai T, Hirose M, Hamano Y, Kagawa T, Murakami A, Kida H, Kumanogoh A, **Inoue Y**. Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. *Can Respir J.* 2022 Mar 29;2022:1107673. doi: 10.1155/2022/1107673. eCollection 2022.
24. Cottin V, Tomassetti S, Valenzuela C, Walsh S, Antoniou K, Bonella F, Brown KK, Collard HR, Corte TJ, Flaherty K, Johannson KA, Kolb M, Kreuter M, **Inoue Y**, Jenkins G, Lee JS, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers J, Nathan SD, Poletti V, Quadrelli S, Raghu G, Rajan SK, Ravaglia C, Remy-Jardin M, Renzoni E, Richeldi L, Spagnolo P, Troy L, Wijsenbeek M, Wilson KC, Wuyts W, Wells AU, Ryerson C. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. *Am J Respir Crit Care Med.* 2022 Mar 30. doi: 10.1164/rccm.202111-2607PP.
25. D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara H, Takeshita A, Nishihama K, Okano T, Saiki H, Okano Y, Tomaru A, Fridman D'Alessandro V, Shiraishi M, Mizoguchi A, Ono R, Ohtsuka J, Fukumura M, Nosaka T, Mi X, Shukla D, Kataoka K, Kondoh Y, Hirose M, Arai

- T, **Inoue Y**, Yano Y, Mackie RI, Cann I, Gabazza EC. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. *Nat Commun.* 2022 Mar 23;13(1):1558. doi: 10.1038/s41467-022-29064-3.
26. Futami Y, Takeda Y, Koba T, Narumi R, Nojima Y, Ito M, Nakayama M, Ishida M, Yoshimura H, Naito Y, Fukushima K, Takimoto T, Edahiro R, Matsuki T, Nojima S, Hirata H, Koyama S, Iwahori K, Nagatomo I, Shirai Y, Suga Y, Satoh S, Futami S, Miyake K, Shiroyama T, **Inoue Y**, Adachi J, Tomonaga T, Ueda K, Kumanogoh A. Identification of CD14 and lipopolysaccharide-binding protein as novel biomarkers for sarcoidosis using proteomics of serum extracellular vesicles. *Int Immunol.* 2022 Jun 4;34(6):327-340. doi: 10.1093/intimm/dxac009.
27. Arai T, Hirose M, Kagawa T, Hatsuda K, **Inoue Y**. Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis. *J Thorac Dis.* 2022 Feb;14(2):278-294. doi: 10.21037/jtd-21-1418.
28. Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, **Inoue Y**. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. *BMJ Open Respir Res.* 2022 Mar;9(1):e001167. doi: 10.1136/bmjresp-2021-001167.
29. Brown KK, **Inoue Y**, Flaherty KR, Martinez FJ, Cottin V, Bonella F, Cerri S, Danoff SK, Jouneau S, Goeldner RG, Schmidt M, Stowasser S, Schlenker-Herceg R, Wells AU. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. *Respirology.* 2022 Feb 27. doi: 10.1111 resp.14231.
30. Katayama K, Arai T, Kobayashi T, Shintani S, Takeuchi N, Matsuda Y, Sugimoto C, Inoue Y, Takeda M, Kasai T, Akira M, **Inoue Y**. Pleuroparenchymal Fibroelastosis with a Predominantly Airway-centered Distribution: A Late Complication of Chemotherapy. *Intern Med.* 2022;61(4):533-540.
31. Enomoto T, **Inoue Y**, Adachi Y, Kouno S, Inagaki Y, Azuma K, Katayama K, Takeuchi N, Matsuda Y. Limitations of End-Tidal CO₂ Measured with a Portable Capnometer to Estimate PaCO₂ for Patients with Respiratory Disease. *Turk Thorac J.* 2021 May;22(3):212-216. doi: 10.5152/TurkThoracJ.2021.20032.
32. Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Fujita Y, Hayashi S, **Inoue Y**. Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias. *Can Respir J.* 2021 Dec 20;2021:4595019. doi: 10.1155/2021/4595019.
33. Langford B, Diamantopoulos A, Maher TM, **Inoue Y**, Rohr KB, Baldwin M. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework. *Adv Ther.* 2022 Feb;39(2):1045-1054.
34. Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Carvalho CRR, Harari S, Koslow M, Grutters JC, **Inoue Y**, Gupta N, Johnson SR. COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition. *Chest.* 2021 Dec 21:S0012-3692(21)05166-7.
35. Matsuda Y, Kosugi T, Yamanaka M, Fukumori T, Inoue A, Horiki M, Matsunuma R, Kataoka Y, Kitamura H, Kataoka K, Matsuoka H, Tokoro A, **Inoue Y**. Expectations of respiratory physicians from psychologists in palliative care for patients with non-cancer respiratory diseases. *Respir Investigig.* 2022 Mar;60(2):309-317.
36. Shintani R, Sekine A, Murohashi K, Otoshi R, Kasuya T, Oda T, Baba T, Komatsu S, Ogura T, **Inoue Y**. Successful Treatment of Chylothorax and Chylopericardium by Radiotherapy in Lung Cancer. *Intern Med.* 2021 Nov 20. doi: 10.2169/internalmedicine.8293-21.
37. Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, **Inoue Y**. The psychometric properties of the

- King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases. *Eur Respir J.* 2021 Nov 11;2101790. doi: 10.1183/13993003.01790-2021
38. Sakurai T, Arai T, Hirose M, Kojima K, Sakamoto T, Matsuda Y, Sugimoto C, Yoon HE, **Inoue Y.** Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis. *Orphanet J Rare Dis.* 2021 Nov 3;16(1):466
39. Lancaster L, Bonella F, **Inoue Y**, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. *Respirology.* 2021 Oct 5. doi: 10.1111/resp.14154. Online ahead of print.
40. Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, **Inoue Y**, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. *Respir Investig.* 2021 Sep 30:S2212-5345(21)00082-4.
41. **Inoue Y**, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T, Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. *Respir Med.* 2021 Aug 12;187:106574.
42. Flaherty KR, Wells AU, Cottin V, Devaraj A, **Inoue Y**, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD trial investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. *Eur Respir J.* 2021 Sep 2:2004538.
43. Nakamura Y, Takimoto T, Kobayashi T, Tachibana K, Kasai T, Akira M, Arai T, **Inoue Y**. Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. *Respir Med Case Rep.* 2021 Aug 18;34:101498.
44. Arai T, Matsuoka H, Hirose M, Kida H, Yamamoto S, Ogata Y, Mori M, Hatsuda K, Sugimoto C, Tachibana K, Akira M, **Inoue Y**. Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. *BMJ Open Respir Res.* 2021 Jul;8(1):e000889.
45. Enomoto N, Homma S, Inase N, Kondoh Y, Saraya T, Takizawa H, **Inoue Y**, Ishii H, Taguchi Y, Izumi S, Yamano Y, Tanino Y, Nishioka Y, Toyoshima M, Yokomura K, Imokawa S, Koshimizu N, Sano T, Akamatsu T, Mukae H, Kato M, Hamada N, Chiba H, Akagawa S, Muro S, Uruga H, Matsuda H, Kaida Y, Kanai M, Mori K, Masuda M, Hozumi H, Fujisawa T, Nakamura Y, Ogawa N, Suda T. Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. *Thorax.* 2021 Jul 16:thoraxjnl-2020-216263. doi: 10.1136/thoraxjnl-2020-216263. Online ahead of print.
46. Mizukoshi F, Kobayashi N, Kirikae F, Ohta K, Tsuyuguchi K, Yamada N, **Inoue Y**, Horiba M, Kawata N, Ichinose A, Miyoshi-Akiyama T, Kiritani R, Funatogawa K, Kirikae T. Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan. *mSphere.* 2021 Aug 25;6(4):e0097820.
47. Sauter M, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R,

- O'Callaghan F, Qin J, Sander V, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen A, Kingswood JC; TOSCA investigators. Rare manifestations and malignancies in tuberous sclerosis complex: findings from the Tuberous Sclerosis registry to increase disease awareness (TOSCA). *Orphanet J Rare Dis.* 2021 Jul 6;16(1):301.
48. Matsuda Y, Morita T, Matsumoto H, Hosoi K, Kusama K, Kohashi Y, Morishita H, Kaku S, Ariyoshi K, Oyamada S, Inoue Y, Iwase S, Yamaguchi T, Nishikawa M. Predictors of Morphine Efficacy for Dyspnea in Inpatients with Chronic Obstructive Pulmonary Disease: A Secondary Analysis of JORTC-PAL 07. *Palliat Med Rep.* 2021 Jan 7;2(1):15-20.
49. Azuma K, Takimoto T, Kasai T, Hirose M, Hatsuda K, Sugimoto C, Arai T, Akira M, Inoue Y. Diagnostic yield and safety of bronchfiberscopy for pulmonary alveolar proteinosis. *Respir Investig.* 2021 May 6:S2212-5345(21)00073-3. doi: 10.1016/j.resinv.2021.03.012. Online ahead of print.
50. Hirose M, Arai T, Sugimoto C, Takimoto T, Sugawara R, Minomo S, Shintani S, Takeuchi N, Katayama K, Inoue Y, Kagawa T, Kasai T, Akira M, Inoue Y. B cell-activating factors in autoimmune pulmonary alveolar proteinosis. *Orphanet J Rare Dis.* 2021 Mar 2;16(1):115. doi: 10.1186/s13023-021-01755-y.
51. Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Miyawaki S, Dofuku S, Maeda Y, Nii T, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Sonehara K, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. *Nat Commun.* 2021 Feb 15;12(1):1032. doi: 10.1038/s41467-021-21011-y.
52. Yoshida S, Tsuyuguchi K, Kobayashi T, Inoue Y, Suzuki K. Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in *Mycobacterium abscessus* complex isolates and evaluation of the accumulation of intrinsic macrolide resistance. *J Med Microbiol.* 2021 Mar;70(3). doi: 10.1099/jmm.0.001326. Epub 2021 Feb 11.
53. Tanabe N, Kumamaru H, Tamura Y, Taniguchi H, Emoto N, Yamada Y, Nishiyama O, Tsujino I, Kuraishi H, Nishimura Y, Kimura H, Inoue Y, Morio Y, Nakatsumi Y, Satoh T, Hanaoka M, Kusaka K, Sumitani M, Handa T, Sakao S, Kimura T, Kondoh Y, Nakayama K, Tanaka K, Ohira H, Nishimura M, Miyata H, Tatsumi K; JRPHS Group. Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. *Circ J.* 2021 Mar 25;85(4):333-342.
54. Enomoto T, Takimoto T, Kagawa T, Tachibana K, Sugimoto C, Arai T, Sakurai T, Kasai T, Akira M, Hayashi S, Inoue Y. Histologically Proven Dendriform Pulmonary Ossification: A Five-case Series. *Intern Med.* 2021 Feb 1. doi: 10.2169/internalmedicine.5906-20. Online ahead of print.
55. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. *Chest.* 2021 Mar;159(3):1107-1125.
56. Kobayashi T, Tsuyuguchi K, Yoshida S, Kimura Y, Tsuji T, Minomo S, Kurahara Y, Inoue Y, Suzuki K. Resumption/efficacy and safety of an azithromycin-containing regimen against *Mycobacterium avium* complex lung

disease in patients who experienced adverse effects with a clarithromycin-containing regimen. *Respir Investig*. 2021 Mar;59(2):212-217.

57. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, **Inoue Y**, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. *Radiology*. 2021 Mar;298(3):550-566.
58. Adachi Y, Takimoto T, Takeda M, Matsumoto K, Takeuchi N, Kagawa T, Sakamoto T, Kasai T, Sugimoto C, **Inoue Y**, Tachibana K, Arai T, Inoue Y. Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case. *Respir Med Case Rep*. 2020 Dec 1;31:101313.
59. Takizawa A, Kamita M, Kondoh Y, Bando M, Kuwana M, Inoue Y. Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. *Curr Med Res Opin*. 2021 Feb;37(2):327-339.
60. de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D'Amato L, Beure d'Augères G, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Kingswood JC, Jansen AC; TOSCA Consortium and TOSCA Investigators. Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. *J Neurodev Disord*. 2020 Sep 1;12(1):24.
61. Trapnell BC, **Inoue Y**, Bonella F, Morgan C, Jouneau S, Bendstrup E, Campo I, Papiris SA, Yamaguchi E, Cetinkaya E, Ilkovich MM, Kramer MR, Veltkamp M, Kreuter M, Baba T, Ganslandt C, Tarnow I, Waterer G, Jouhikainen T; IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. *N Engl J Med*. 2020 Oct 22;383(17):1635-1644
62. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dolphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, **Inoue Y**, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020 Aug 1;202(3):e36-e69
63. Katayama K, Hirose M, Arai T, Hatsuda K, Tachibana K, Sugawara R, Sugimoto C, Kasai T, Akira M, **Inoue Y**. Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis. *Orphanet J Rare Dis*. 2020 Sep 29;15(1):272
64. Arai T, Akira M, Sugimoto C, Tachibana K, Inoue Y, Shintani S, Okuma T, Kasai T, Hayashi S, **Inoue Y**. Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. *J Thorac Dis*. 2020 Aug;12(8):4132-4147
65. Yanagihara T, **Inoue Y**. Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases. *Curr Opin Pulm Med*. 2020 Sep;26(5):507-517.
66. Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San José Estépar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, **Inoue Y**, Lynch DA. Interstitial lung abnormalities detected incidentally on

- CT: a Position Paper from the Fleischner Society. *Lancet Respir Med.* 2020 Jul;8(7):726-737.
67. Arai T, Kasai T, Shimizu K, Kawahara K, Katayama K, Sugimoto C, Hirose M, Okamoto H, Tachibana K, Akira M, **Inoue Y**. Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. *Intern Med.* 2020 Oct 15;59(20):2539-2546
68. Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, Hamada N, Taniguchi H, Hattori N, Nishioka Y, Tanizawa K, Johkoh T, Yokoyama T, Mori K, Taguchi Y, Ebina M, Inase N, Hagiwara K, Ohnishi H, Mukae H, **Inoue Y**, Kuwano K, Chiba H, Ohta K, Tanino Y, Sakai F, Sugiyama Y. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. *ERJ Open Res.* 2020 May 26;6(2):00184-2019
69. Kobayashi T, Tsuyuguchi K, Yoshida S, Kurahara Y, Minomo S, **Inoue Y**, Suzuki K. Serum immunoglobulin a antibodies to glycopeptidolipid core antigen for Mycobacteroides abscessus complex lung disease. *Int J Mycobacteriol.* 2020 Jan-Mar;9(1):76-82
70. Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, **Inoue Y**. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. *BMJ Open Respir Res.* 2020 May;7(1):e000558.
71. Arai T, **Inoue Y**. Is corticosteroid use truly not associated with improved outcomes in AE-IPF? *Respirology.* 2020 Jun;25(6):659
72. Yoshida S, Iwamoto T, Kobayashi T, Nomoto R, **Inoue Y**, Tsuyuguchi K, Suzuki K. Two New Cases of Pulmonary Infection by Mycobacterium shigaense, Japan. *Emerg Infect Dis.* 2020 Nov;26(11):2728-2732
73. Yoshida S, Iwamoto T, Arikawa K, Sekizuka T, Kuroda M, **Inoue Y**, Mitarai S, Tsuji T, Tsuyuguchi K, Suzuki K. Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient. *J Antimicrob Chemother.* 2020 Jul 1;75(7):1722-1725
74. Minomo S, Arai T, Higo H, Tsuji T, Tachibana K, Akira M, **Inoue Y**. Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum. *Respir Investig.* 2020 Jul;58(4):262-268
75. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, **Inoue Y**, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Chest.* 2020 Apr 7. pii: S0012-3692(20)30673-5
76. **Inoue Y**, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. *Chest.* 2020 Apr 5. pii: S0012-3692(20)30569-9
77. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, **Inoue Y**, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology.* 2020 Apr 7:201365.

78. Wells AU, Flaherty KR, Brown KK, **Inoue Y**, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med*. 2020 Mar 5. pii: S2213-2600(20)30036-9
79. Inagaki Y, Tachibana K, **Inoue Y**, Kasai T, **Inoue Y**. Severe clopidogrel-induced DRESS with eosinophilic pneumonia associated with Epstein-Barr virus reactivation. *Respirol Case Rep*. 2020 Feb 20;8(3):e00541.
80. Tateishi T, Johkoh T, Sakai F, Miyazaki Y, Ogura T, Ichikado K, Suda T, Taguchi Y, **Inoue Y**, Takemura T, Colby TV, Sumikawa H, Fujimoto K, Arakawa H, Raoof S, Inase N. High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. *Jpn J Radiol*. 2020 Feb 26. doi: 10.1007/s11604-020-00932-6.
81. Nakata K, Sugi T, Kuroda K, Yoshizawa K, Takada T, Tazawa R, Ueda T, Aoki A, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Hirano T, Handa T, Hirai T, **Inoue Y**, Arai T, Asakawa K, Sakagami T, Tanaka T, Mikami A, Kitamura N. Validation of a new serum granulocyte-macrophage colony-stimulating factor autoantibody testing kit. *ERJ Open Res*. 2020 Jan 27;6(1). pii: 00259-2019
82. Liu H, Osterburg AR, Flury J, Swank Z, McGraw DW, Gupta N, Wikenheiser-Brokamp KA, Kumar A, Tazi A, **Inoue Y**, Hirose M, McCormack FX, Borchers MT. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. *JCI Insight*. 2020 Feb 27;5(4). pii: 132048.
83. Ichinose M, Fukushima Y, **Inoue Y**, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2019 Dec 23;14:2993-3002.
84. Ichinose M, Fukushima Y, **Inoue Y**, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. *Int J Chron Obstruct Pulmon Dis*. 2019 Dec 23;14:2979-2991
85. Kondoh Y, Azuma A, **Inoue Y**, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S. Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial. *Am J Respir Crit Care Med*. 2020 Jan 9
86. Varone F, **Inoue Y**, Richeldi L. Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis. *Respirology*. 2020 Jan;25(1):20-22
87. Matsuda Y, Morita T, Matsumoto H, Hosoi K, Kusama K, Kohashi Y, Morishita H, Kaku S, Ariyoshi K, Oyamada S, **Inoue Y**, Iwase S, Yamaguchi T, Nishikawa M. Morphine for dyspnoea in chronic obstructive pulmonary disease: a before-after efficacy study. *BMJ Support Palliat Care*. 2019 Nov 15. pii: bmjspcare-2019-001929
88. Minomo S, Arai T, Tachibana K, Matsui H, Kasai T, Akira M, **Inoue Y**. Airway-centered Fibroelastosis

- Accompanied by Subpleural Lesions of Unknown Cause in a Young Man Who Later Developed Pulmonary Hypertension. *Intern Med.* 2020 Mar 1;59(5):695-700
89. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, **Inoue Y**, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med.* 2019 Oct 31;381(18):1718-1727
90. Tominaga J, Bankier AA, Lee KS, Leung AN, Remy-Jardin M, Akira M, Arakawa H, Boiselle PM, Franquet T, Fujimoto K, Gevenois PA, Goo JM, Grenier PA, Hatabu H, Ichikado K, Im JG, Johkoh T, Lee KN, Lynch DA, Noma S, Song JW, Sakai F, Sugiyama Y; Study Group of Diffuse Interstitial Lung Disease in Japan. Inter-observer agreement in identifying traction bronchiectasis on computed tomography: its improvement with the use of the additional criteria for chronic fibrosing interstitial pneumonia. *Jpn J Radiol.* 2019 Nov;37(11):773-780.
91. Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, **Inoue Y**, Arai T, Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N, Nakata K. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. *N Engl J Med.* 2019 Sep 5;381(10):923-932.
92. Ogura T, Takigawa N, Tomii K, Kishi K, **Inoue Y**, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. *Respir Investig.* 2019 Nov;57(6):512-533
93. Song JW, Ogura T, **Inoue Y**, Xu Z, Quaresma M, Stowasser S, Stansen W, Crestani B. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON. *Respirology.* 2020 Apr;25(4):410-416.
94. Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respir Med.* 2019 Sep;7(9):771-779
95. Yoshida S, Tsuyuguchi K, Chikamatsu K, Aono A, Takaki A, Mitarai S, Kobayashi T, **Inoue Y**, Suzuki K. Antimicrobial susceptibility patterns and MICs among non-photochromogenic rapidly growing Mycobacteroides and Mycolicibacterium species. *J Med Microbiol.* 2019 Sep;68(9):1279-1286
96. Nakagawa T, Hashimoto H, Yagi M, Kogure Y, Sekimizu M, Saito AM, Ogawa K, **Inoue Y**. Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol. *BMJ Open Respir Res.* 2019 May 30;6(1):e000434.
97. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, **Inoue Y**, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2019 Nov 1;200(9):1146-1153

98. Lancaster L, Crestani B, Hernandez P, **Inoue Y**, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. *BMJ Open Respir Res.* 2019 Mar 25;6(1):e000397
99. Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; **GALATHEA Study Investigators**; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med.* 2019 Sep 12;381(11):1023-1034
100. Enomoto N, Egashira R, Tabata K, Hashisako M, Kitani M, Waseda Y, Ishizuka T, Watanabe S, Kasahara K, Izumi S, Shiraki A, Miyamoto A, Kishi K, Kishaba T, Sugimoto C, **Inoue Y**, Kataoka K, Kondoh Y, Tsuchiya Y, Baba T, Sugiura H, Tanaka T, Sumikawa H, Suda T. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. *Sci Rep.* 2019 May 14;9(1):7355
101. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, **Inoue Y**, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danelchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2019 Jul 15;200(2):199-208
102. Watanabe K, Ishii H, Kiyomi F, Terasaki Y, Hebisawa A, Kawabata Y, Johkoh T, Sakai F, Kondoh Y, **Inoue Y**, Azuma A, Suda T, Ogura T, Inase N, Homma S; Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases in Japan. Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal. *Respir Investig.* 2019 Jul;57(4):312-320
103. Fujisawa T, Mori K, Mikamo M, Ohno T, Kataoka K, Sugimoto C, Kitamura H, Enomoto N, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Hashisako M, Tanaka T, Terasaki Y, Kunugi S, Kitani M, Okuda R, Horiike Y, Enomoto Y, Yasui H, Hozumi H, Suzuki Y, Nakamura Y, Fukuoka J, Johkoh T, Kondoh Y, Ogura T, **Inoue Y**, Hasegawa Y, Inase N, Homma S, Suda T. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. *Eur Respir J.* 2019 May 18;53(5). pii: 1802243
104. Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen A,

- Kingswood JC; TOSCA Consortium and TOSCA Investigators. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. *Epilepsia Open*. 2018 Dec 21;4(1):73-84.
105. Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX; NIH Rare Lung Disease Consortium. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. *Eur Respir J*. 2019 Apr 4;53(4). pii: 1802066
106. Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Edahiro R, Hamasaki T, Inoue Y; Osaka Acute Exacerbation of Interstitial Pneumonia Research Group. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. *Respirology*. 2019 Jul;24(7):658-666
107. Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, Young LR, McCormack FX, Inoue Y. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. *PLoS One*. 2019 Feb 28;14(2):e0212776
108. Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU. Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. *Respir Med*. 2019 Jan;146:42-48.
109. Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. *Eur Respir Rev*. 2018 Dec 21;27(150). pii: 180075
110. Minomo S, Kitaichi M, Arai T, Matsui H, Akira M, Inoue Y. Pulmonary Veno-occlusive Disease: A Surgical Lung Biopsy-proven and Autopsied Case Radiologically Mimicking Hypersensitivity Pneumonitis at the Time of a Transbronchial Lung Biopsy. *Intern Med*. 2019 Apr 1;58(7):955-964
111. Kumar A, Abdelmalak B, Inoue Y, Culver D. Blood testing in the diagnosis of pulmonary alveolar proteinosis - Authors' reply. *Lancet Respir Med*. 2018 Nov;6(11):e55
112. Futami S, Arai T, Hirose M, Sugimoto C, Ikegami N, Akira M, Kasai T, Kitaichi M, Hayashi S, Inoue Y. Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study. *Orphanet J Rare Dis*. 2018 Oct 20;13(1):182
113. Sonobe S, Arai T, Tanimoto Y, Sugimoto C, Kitaichi M, Akira M, Kasai T, Hirose M, Inoue Y. Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. *Intern Med*. 2019 Feb 15;58(4):569-574
114. Yoshida S, Suga S, Ishikawa S, Mukai Y, Tsuyuguchi K, Inoue Y, Yamamoto T, Wada T. Mycobacterium caprae Infection in Captive Borneo Elephant, Japan. *Emerg Infect Dis*. 2018 Oct;24(10):1937-1940.
115. de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augères GB, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Kingswood JC, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC; TOSCA Consortium and TOSCA Investigators. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. *Orphanet J Rare Dis*. 2018 Sep 10;13(1):157
116. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L,

- Inoue Y**, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2018 Sep 1;198(5):e44-e68
117. Matsuda Y, Morita T, Miyaji T, Ogawa T, Kato K, Kawaguchi T, Tokoro A, Iwase S, Yamaguchi T, **Inoue Y**. Morphine for Refractory Dyspnea in Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05). *J Palliat Med.* 2018 Aug 21
118. Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, **Inoue Y**, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. *Respir Investig.* 2018 Jul;56(4):268-291
119. Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Shintani A, Fujisawa T, Suda T, Arita M, Baba T, Ichikado K, **Inoue Y**, Kishi K, Kishaba T, Nishiyama O, Ogura T, Tomii K, Homma S. Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy. *PLoS One.* 2018 Mar 28;13(3):e0193608.
120. Hirano T, Ohkouchi S, Tode N, Kobayashi M, Ono M, Satoh T, Mitsuishi Y, Watanabe A, Tabata M, Irokawa T, Ogawa H, Sugiura H, Kikuchi T, Akasaka K, Tazawa R, **Inoue Y**, Nakata K, Kurosawa H, Ichinose M. Peripheral alveolar nitric oxide concentration reflects alveolar inflammation in autoimmune pulmonary alveolar proteinosis. *ERJ Open Res.* 2018 Mar 23;4(1). pii: 00071-2017.
121. Kobayashi T, Tsuyuguchi K, Arai T, Tsuji T, Maekura T, Kurahara Y, Sugimoto C, Minomo S, Nakao K, Tokura S, Sasaki Y, Hayashi S, **Inoue Y**, Suzuki K. Change in lung function in never-smokers with nontuberculous mycobacterial lung disease: A retrospective study. *J Clin Tuberc Other Mycobact Dis.* 2018 Mar 14;11:17-21
122. Arai T, **Inoue Y**. Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. *Respirology.* 2018 May;23(5):546-547
123. Kobayashi T, Tsuyuguchi K, Yoshida S, Kurahara Y, Ikegami N, Naito M, Sonobe S, Maekura T, Tsuji T, Minomo S, **Inoue Y**, Suzuki K. Mycobacterium abscessus subsp. abscessus Lung Disease: Drug Susceptibility Testing in Sputum Culture Negative Conversion. *Int J Mycobacteriol.* 2018 Jan-Mar;7(1):69-75
124. Lynch DA, Sverzellati N, Travis WD, Colby TV, **Inoue Y**, Nicholson AG, Raoof S, Richeldi L, Ryerson CJ, Ryu JH. Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. *Lancet Respir Med.* 2018 Feb;6(2):e7
125. Kumar A, Abdelmalak B, **Inoue Y**, Culver DA. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. *Lancet Respir Med.* 2018 Jul;6(7):554-565
126. Yoshida S, Tsuyuguchi K, Kobayashi T, Tomita M, **Inoue Y**, Hayashi S, Suzuki K. Association between sequevar and antibiotic treatment outcome in patients with Mycobacterium abscessus complex infections in Japan. *J Med Microbiol.* 2018 Jan;67(1):74-82
127. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, **Inoue Y**, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med.* 2018 Feb;6(2):138-153

128. Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA, Ryu JH, Seyama K, **Inoue Y**, Downey GP, Han MK, Colby TV, Wikenheiser-Brokamp KA, Meyer CA, Smith K, Moss J, McCormack FX; ATS Assembly on Clinical Problems. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2017 Nov 15;196(10):1337-1348
129. Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, **Inoue Y**, Le Mauff F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. *BMJ Open Respir Res.* 2017 Sep 17;4(1):e000212
130. Koba T, Arai T, Kitaichi M, Kasai T, Hirose M, Tachibana K, Sugimoto C, Akira M, Hayashi S, **Inoue Y**. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients. *Respirology.* 2018 Mar;23(3):331-338
131. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, **Inoue Y**, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J.* 2017 Aug 31;50(2). pii: 1700936
132. Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Ando M, Murotani K, Mishima M, **Inoue Y**, Ogura T, Bando M, Hagiwara K, Suda T, Chiba H, Takahashi H, Sugiyama Y, Homma S. Disease severity staging system for idiopathic pulmonary fibrosis in Japan. *Respirology.* 2017 Nov;22(8):1609-1614.
133. Kitamura N, Seyama K, **Inoue Y**, Nagai K, Suzuki M, Moriyama H, Takada T, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Arai T, Sugimoto C, Hattori N, Watanabe K, Tamada T, Akazawa K, Tanaka T, Nakata K. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study. *Pharmacoepidemiol Drug Saf.* 2017 Oct;26(10):1182-1189
134. Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T, Akira M, Kitaichi M, Hayashi S, **Inoue Y**. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. *Respirology.* 2017 Oct;22(7):1363-1370.
135. Kobayashi T, Kitaichi M, Tachibana K, Kishimoto Y, Inoue Y, Kagawa T, Maekura T, Sugimoto C, Arai T, Akira M, **Inoue Y**. A Cryptogenic Case of Fulminant Fibrosing Organizing Pneumonia. *Intern Med.* 2017;56(10):1185-1191
136. Tokura S, Akira M, Okuma T, Tazawa R, Arai T, Sugimoto C, Matsumuro A, Hirose M, Takada T, Nakata K, Ishii H, Kasahara Y, Hojo M, Ohkouchi S, Tsuchihashi Y, Yokoba M, Eda R, Nakayama H, Nei T, Morimoto K, Nasuhara Y, Ebina M, Ichiwata T, Tatsumi K, Yamaguchi E, **Inoue Y**. A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar Proteinosis. *Ann Am Thorac Soc.* 2017 Sep;14(9):1403-1411
137. Matsuda Y, Maeda I, Tachibana K, Nakao K, Sasaki Y, Sugimoto C, Arai T, Tokoro A, Akira M, **Inoue Y**. Low-Dose Morphine for Dyspnea in Terminally Ill Patients with Idiopathic Interstitial Pneumonias. *J Palliat Med.* 2017

Aug;20(8):879-883

138. Hamano Y, Kida H, Ihara S, Murakami A, Yanagawa M, Ueda K, Honda O, Tripathi LP, Arai T, Hirose M, Hamasaki T, Yano Y, Kimura T, Kato Y, Takamatsu H, Otsuka T, Minami T, Hirata H, Inoue K, Nagatomo I, Takeda Y, Mori M, Nishikawa H, Mizuguchi K, Kijima T, Kitaichi M, Tomiyama N, **Inoue Y**, Kumanogoh A. Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. *Sci Rep.* 2017 Feb 23;7:43201.
139. Kobayashi T, Tsuyuguchi K, Yoshida S, Kurahara Y, Tsuji T, Nakao K, Sasaki Y, Hayashi S, **Inoue Y**, Suzuki K. A case of Mycobacterium abscessus subsp. massiliense lung disease complicated by lipoid pneumonia. *Int J Tuberc Lung Dis.* 2017 Jan 1;21(1):124-126.
140. Azuma A, Taniguchi H, **Inoue Y**, Kondoh Y, Ogura T, Homma S, Fujimoto T, Sakamoto W, Sugiyama Y, Nukiwa T. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials. *Respirology.* 2017 May;22(4):750-757
141. McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, **Inoue Y**, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; ATS/JRS Committee on Lymphangioleiomyomatosis. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. *Am J Respir Crit Care Med.* 2016 Sep 15;194(6):748-61.
142. Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, **Inoue Y**, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. *Orphanet J Rare Dis.* 2016 Aug 31;11(1):115.
143. Kohashi Y, Arai T, Sugimoto C, Tachibana K, Akira M, Kitaichi M, Hayashi S, **Inoue Y**. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy. *Respiration.* 2016;92(4):220-228.
144. Akira M, **Inoue Y**, Arai T, Sugimoto C, Tokura S, Nakata K, Kitaichi M; Osaka Respiratory Diseases Symposia Group. Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis. *AJR Am J Roentgenol.* 2016 Sep;207(3):544-51
145. Takada T, Mikami A, Kitamura N, Seyama K, **Inoue Y**, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K, Tanaka T, Yagi K, Young LR, McCormack FX, Nakata K. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. *Ann Am Thorac Soc.* 2016 Nov;13(11):1912-1922.
146. Hamada T, Samukawa T, Kumamoto T, Hatanaka K, Tsukuya G, Yamamoto M, Machida K, Watanabe M, Mizuno K, Higashimoto I, **Inoue Y**, Inoue H. Erratum to: Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease. *BMC Pulm Med.* 2016 Aug 8;16(1):117.
147. Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Kitaichi M, Akira M, Hayashi S, **Inoue Y**. Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. *Respirology.* 2016 Nov;21(8):1431-1437
148. Taniguchi H, Xu Z, Azuma A, **Inoue Y**, Li H, Fujimoto T, Bailes Z, Schlenker-Herceg R, Kim DS. Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. *Respirology.*

149. Campo I, Luisetti M, Gries M, Trapnell BC, Bonella F, Grutters JC, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichikawa T, **Inoue Y**, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis. *Chest*. 2016 Jul;150(1):251-3.
150. Hayashida M, Yasuo M, Hanaoka M, Seyama K, **Inoue Y**, Tatsumi K, Mishima M; Respiratory Failure Research Group of the Ministry of Health, Labour, and Welfare, Japan. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. *Respir Investig*. 2016 May;54(3):193-200
151. Nuñez O, Román A, Johnson SR, **Inoue Y**, Hirose M, Casanova Á, de Garibay GR, Herranz C, Bueno-Moreno G, Boni J, Mateo F, Petit A, Climent F, Soler T, Vidal A, Sánchez-Mut JV, Esteller M, López JI, García N, Gumà A, Ortega R, Plà MJ, Campos M, Ansótegui E, Molina-Molina M, Valenzuela C, Ussetti P, Laporta R, Ancochea J, Xaubet A, Pollán M, Pujana MA. Study of breast cancer incidence in patients of lymphangioleiomyomatosis. *Breast Cancer Res Treat*. 2016 Feb;156(1):195-201
152. Ando K, Okada Y, Akiba M, Kondo T, Kawamura T, Okumura M, Chen F, Date H, Shiraishi T, Iwasaki A, Yamasaki N, Nagayasu T, Chida M, **Inoue Y**, Hirai T, Seyama K, Mishima M; Respiratory Failure Research Group of the Japanese Ministry of Health, Labour, and Welfare. Lung Transplantation for Lymphangioleiomyomatosis in Japan. *PLoS One*. 2016 Jan 15;11(1):e0146749
153. Kobayashi T, Arai T, Hirose M, Homma T, Matsumuro A, Sugimoto C, Kitaichi M, Akira M, **Inoue Y**. Temporary remission of autoimmune pulmonary alveolar proteinosis after infectious episodes. *Sarcoidosis Vasc Diffuse Lung Dis* 2017; 34; 85-90
154. Arai T, **Inoue Y**, Akira M, Nakata K, Kitaichi M. Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis. *Intern Med*. 2015;54(24):3177-80
155. Saito A, Nikolaidis NM, Amlal H, Uehara Y, Gardner JC, LaSance K, Pitstick LB, Bridges JP, Wikenheiser-Brokamp KA, McGraw DW, Woods JC, Sabbagh Y, Schiavi SC, Altinićik G, Jakopović M, **Inoue Y**, McCormack FX. Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. *Sci Transl Med*. 2015 Nov 11;7(313)
156. Miyazaki Y, Azuma A, Inase N, Taniguchi H, Ogura T, Inoue E, Takeuchi M, Yoshizawa Y, Sugiyama Y, Kudoh S; IPF trial group in Japan. Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis. *Respir Investig*. 2015 Nov;53(6):288-95, *Sci Transl Med*. 2015 Nov 11;7(313)
157. Hamada T, Samukawa T, Kumamoto T, Hatanaka K, Tsukuya G, Yamamoto M, Machida K, Watanabe M, Mizuno K, Higashimoto I, **Inoue Y**, Inoue H. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease. *BMC Pulm Med*. 2015 Sep 30;15:110.
158. Costabel U, **Inoue Y**, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A. *Am J Respir Crit Care Med*. 2016 Jan 15;193(2):178-85
159. Tominaga J, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, Colby TV, Ogura T, **Inoue Y**, Taniguchi H, Homma S, Taguchi Y, Sugiyama Y. Diagnostic certainty of idiopathic pulmonary fibrosis/usual interstitial pneumonia: The effect of the integrated clinico-radiological assessment. *Eur J Radiol*. 2015 Dec;84(12):2640-5.

160. Ogura T, Azuma A, **Inoue Y**, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, Kudoh S, Nukiwa T. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
161. Akasaka K, Tanaka T, Kitamura N, Ohkouchi S, Tazawa R, Takada T, Ichiwata T, Yamaguchi E, Hirose M, Arai T, Nakano K, Nei T, Ishii H, Handa T, **Inoue Y**, Nakata K. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. *BMC Pulm Med*. 2015 Aug 12;15:88
162. Gupta N, Meraj R, Tanase D, James LE, Seyama K, Lynch DA, Akira M, Meyer CA, Ruoss SJ, Burger CD, Young LR, Almoosa KF, Veeraraghavan S, Barker AF, Lee AS, Dilling DF, **Inoue Y**, Cudzilo CJ, Zafar MA, McCormack FX. *Eur Respir J*. 2015 Oct;46(4):1196-9.
163. Akasaka K, Tanaka T, Maruyama T, Kitamura N, Hashimoto A, Ito Y, Watanabe H, Wakayama T, Arai T, Hayashi M, Moriyama H, Uchida K, Ohkouchi S, Tazawa R, Takada T, Yamaguchi E, Ichiwata T, Hirose M, Arai T, **Inoue Y**, Kobayashi H, Nakata K. A mathematical model to predict protein wash out kinetics during whole-lung lavage in autoimmune pulmonary alveolar proteinosis. *Am J Physiol Lung Cell Mol Physiol*. 2015 Jan 15;308(2):L105-17.
164. Nakatani T, Arai T, Kitaichi M, Akira M, Tachibana K, Sugimoto C, Hirooka A, Tsuji T, Minomo S, Hayashi S, **Inoue Y**. Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity?, *Eur Respir J*. 2015 Feb 19. pii: ERJ-02147-2014. [Epub ahead of print].
165. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, **Inoue Y**, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Mauff F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014 May 29;370(22):2071-82.
166. Richeldi L, Cottin V, Flaherty KR, Kolb M, **Inoue Y**, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Mauff F, Stowasser S, Collard HR. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respir Med*. 2014 Jul;108(7):1023-30.
167. Ogura T, Taniguchi H, Azuma A, **Inoue Y**, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Klüglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis, *Eur Respir J*. 2014 Dec 10. pii: ERJ-01980-2013. [Epub ahead of print]
168. Gupta R, Kitaichi M, **Inoue Y**, Kotloff R, McCormack FX. Lymphatic manifestations of lymphangioleiomyomatosis. *Lymphology*. 2014 Sep;47(3):106-17.
169. Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, **Inoue Y**, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. *Cancer Sci*. 2014 Dec;105(12):1584-90. doi: 10.1111/cas.12550. PMID: 25287435 [PubMed - indexed for MEDLINE]
170. Kanazu M, Arai T, Sugimoto C, Kitaichi M, Akira M, Abe Y, Hozumi Y, Suzuki T, **Inoue Y**. An intractable case of hermansky-pudlak syndrome, *Intern Med* 2014 Nov 15;53(22):2629-2634.
171. Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, Shigemitsu H, Culver DA, Gelfand J, Valeyre D, Sweiss N, Crouser E, Morgenthau AS, Lower EE, Azuma A, Ishihara M, Morimoto S, Yamaguchi T,

- Shijubo N, Grutters JC, Rosenbach M, Li HP, Rottoli P, **Inoue Y**, Prasse A, Baughman RP, Organ Assessment Instrument Investigators TW. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. *Sarcoidosis Vasc Diffuse Lung Dis.* 2014 Apr;31(1):19-27.
172. Arai T, **Inoue Y**, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. *Respir Investig.* 2014 Mar;52(2):136-43.
173. Kinehara Y, Kida H, **Inoue Y**, Hirose M, Nakabayashi A, Takeuchi Y, Hayama Y, Fukushima K, Hirata H, Inoue K, Minami T, Nagatomo I, Takeda Y, Funakoshi T, Kijima T, Kumanogoh A. Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis. *BMC Pulm Med.* 2014 Nov 4;14:172. doi: 10.1186/1471-2466-14-172. PMID: 25366193 [PubMed - in process]
174. Matsuda Y, Tachibana K, Sasaki Y, Tsuyuguchi K, Kitaichi M, **Inoue Y**. Tracheobronchial lesions in eosinophilic pneumonia. *Respir Investig.* 2014 Jan;52(1):21-7.
175. Tokura S, Okuma T, Akira M, Arai T, **Inoue Y**, Kitaichi M. Utility of expiratory thin-section CT for fibrotic interstitial pneumonia. *Acta Radiol.* 2013 Nov 19. doi:pii: 0284185113512300.
176. Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, Koch DE, Stevens C, **Inoue Y**, Yamada Y, Trapnell BC. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. *J Immunol Methods.* 2014 Jan 15;402(1-2):57-70.
177. Ishii H, Seymour JF, Tazawa R, **Inoue Y**, Uchida N, Nishida A, Kogure Y, Saraya T, Tomii K, Takada T, Itoh Y, Hojo M, Ichiwata T, Goto H, Nakata K. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. *BMC Pulm Med.* 2014 Mar 5;14:37.
178. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, **Inoue Y**, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013 Sep 15;188(6):733-48.
179. Arai T, **Inoue Y**, Tachibana K, Tsuyuguchi K, Nishiyama A, Sugimoto C, Sasaki Y, Kagawa T, Matsuda Y, Hayashi S. Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. *Respirology.* 2013 Jan;18(1):117-24, 2013
180. Arai T, **Inoue Y**, Sugimoto C, Otsuka J, Nishiyama A, Inoue Y, Kagawa T, Nakao K, Takeuchi N, Matsumuro A, Hirose M, Nakata K, Akira M, Kitaichi M, Hayashi S. CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. *Respirology.* 2013 Nov 20. doi: 10.1111/resp.12210
181. Nei T, Urano S, Itoh Y, Kitamura N, Hashimoto A, Tanaka T, Motoi N, Kaneko C, Tazawa R, Nakagaki K, Arai T, **Inoue Y**, Nakata K. Light chain (α/λ) ratio of GM-CSF autoantibodies is associated with disease severity in autoimmune pulmonary alveolar proteinosis. *Clin Immunol.* 2013 Dec;149(3):357-64.
182. Young L, Lee HS, **Inoue Y**, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP,

- Trapnell BC, McCormack FX; MILES Trial Group. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. *Lancet Respir Med.* 2013 Aug;1(6):445-52.
183. Tazawa R, **Inoue Y**, Arai T, Takada T, Kasahara Y, Hojo M, Ohkouchi S, Tsuchihashi Y, Yokoba M, Eda R, Nakayama H, Ishii H, Nei T, Morimoto K, Nasuhara Y, Ebina M, Akira M, Ichiwata T, Tatsumi K, Yamaguchi E, Nakata K. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled GM-CSF therapy. *Chest.* 2014 Apr;145(4):729-37
184. Takeuchi N, Arai T, Kitaichi M, **Inoue Y**. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid. *BMJ Case Rep.* 2013 Sep 26;2013.
185. Yoshinobu Matsuda, Kazunobu Tachibana, Yumiko Sasaki, Kazunari Tsuyuguchi, Masanori Kitaichi, **Yoshikazu Inoue**. Tracheobronchial lesions in eosinophilic pneumonia. *Respiratory Investigation.*, 2013 (on line, in press)
186. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, **Inoue Y**, Sakai F, Johkoh T, Fujimoto K, Kudoh S. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. *Int J Clin Oncol* 18(4):743-9, 2013
187. Swigris JJ, Lee HS, Cohen M, **Inoue Y**, Moss J, Singer L, Young LR, McCormack FX. St. George's Respiratory Questionnaire has Longitudinal Construct Validity in Lymphangioleiomyomatosis. *Chest.* 143(6):1671-8, 2013
188. Tsujino K, Takeda Y, Arai T, Shintani Y, Inagaki R, Saiga H, Iwasaki T, Tetsumoto S, Jin Y, Ihara S, Minami T, Suzuki M, Nagatomo I, Inoue K, Kida H, Kijima T, Ito M, Kitaichi M, **Inoue Y**, Tachibana I, Takeda K, Okumura M, Hemler ME, Kumanogoh A. Tetraspanin CD151 Protects against Pulmonary Fibrosis by Maintaining Epithelial Integrity. *Am J Respir Crit Care Med.* 186(2):170-80, 2012
189. Tachibana K, Arai T, Kagawa T, Minomo S, Akira M, Kitaichi M, **Inoue Y**. A Case of Combined Sarcoidosis and Usual Interstitial Pneumonia. *Internal Medicine* 51:1893-7, 2012
190. McCormack FX, **Inoue Y**, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med.* 364(17):1595-606, 2011
191. Ishii H, Tazawa R, Kaneko C, Saraya T, **Inoue Y**, Hamano E, Kogure Y, Tomii K, Terada M, Takada T, Hojo M, Nishida A, Ichiwata T, Trapnell BC, Goto H, Nakata K. Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. *Eur Respir J.* 37(2):465-8, 2011
192. Ohashi K, Sato A, Takada T, Arai T, Kasahara Y, Hojo M, Nei T, Nakayama H, Motoi N, Urano S, Eda R, Yokoba M, Tsuchihashi Y, Nasuhara Y, Ishii H, Ebina M, Yamaguchi E, **Inoue Y**, Nakata K, Tazawa R. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. *Eur. Respir. J.* 2012; 39(3): 777-780.
193. Tachibana K, **Inoue Y**, Nishiyama A, Sugimoto C, Matsumuro A, Hirose M, Kitaichi M, Akira M, Arai T, Hayashi S, **Inoue Y**. Polymyxin-B Hemoperfusion for Acute Exacerbation of Idiopathic Pulmonary Fibrosis:

- Serum IL-7 as a Prognostic Marker. *Sarcoidosis vasculitis and diffuse lung diseases*, 28 : 113-122 2011
194. Akira M, **Inoue Y**, Arai T, Okuma T, Kawata Y. Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. *Thorax*. 66(1):61-5, 2011
195. Ohashi K, Sato A, Takada T, Arai T, Nei T, Kasahara Y, Motoi N, Hojo M, Urano S, Ishii H, Yokoba M, Eda R, Nakayama H, Nasuhara Y, Tsuchihashi Y, Kaneko C, Kanazawa H, Ebina M, Yamaguchi E, Kirchner J, **Inoue Y**, Nakata K, Tazawa R. Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis. *Respir Med*. 106(2):284-93, 2012 Feb
196. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S; Japan NAC Clinical Study Group, Collaborators: Kudoh S, Azuma A, Homma S, Taniguchi H, Ogura T, Mochizuki Y, Sugiyama Y, Nakata K, Munakata M, Nukiwa T, Ishii Y, Yoshimura K, Oritsu M, Yoshizawa Y, Takizawa H, Ohta K, Suzuki E, Chida K, **Inoue Y**, Kohno N, Nishioka Y, Hamada H, Kohno S, Suga M, Taguchi Y, Noma S, Takahashi H, Kanazawa M, Sakai F, Tomii K, Tomioka Y, Takeuchi M. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. *Respirology*. 2012 Apr;17(3):467-77
197. Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan: Betsuyaku T, Sugawara Y, Fujiuchi S, Yamauchi K, Konishi K, Munakata M, Kimura Y, Ishii Y, Sugiyama Y, Kudoh K, Saito T, Yamaguchi T, Mizoo A, Nagai A, Ishizaka A, Yamaguchi K, Yoshimura K, Oritsu M, Fukuchi Y, Takahashi K, Kimura K, Yoshizawa Y, Nagase T, Hisada T, Ohta K, Yoshimori K, Miyazawa Y, Tatsumi K, Sasaki Y, Taniguchi M, Sugita Y, Suzuki E, Saito Y, Nakamura H, Chida K, Kasamatsu N, Hayakawa H, Yasuda K, Saganuma H, Genma H, Tamura R, Shirai T, Shindoh J, Sato S, Taguchi O, Sasaki Y, Ibata H, Yasui M, Nakano Y, Ito M, Kitada S, Kimura H, **Inoue Y**, Yasuba H, Mochizuki Y, Horikawa S, Suzuki Y, Katakami N, Tanimoto Y, Hitsuda Y, Burioka N, Sato T, Kohno N, Yokoyama A, Nishioka Y, Ueda N, Kuwano K, Watanabe K, Aizawa H, Kohno S, Mukae H, Kohrogi H, Kadota J, Tokimatsu I, Miyazaki E, Sasaki T, Kawabata M. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. *Respir Res*. 2011 Oct 28;12:143
198. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan: Betsuyaku T, Sugawara Y, Fujiuchi S, Yamauchi K, Konishi K, Munakata M, Kimura Y, Ishii Y, Kudoh K, Saito T, Yamaguchi T, Mizoo A, Nagai A, Ishizaka A, Yamaguchi K, Yoshimura K, Oritsu M, Fukuchi Y, Takahashi K, Kimura K, Yoshizawa Y, Nagase T, Hisada T, Ohta K, Yoshimori K, Miyazawa Y, Tatsumi K, Taniguchi M, Sugita Y, Suzuki E, Saito Y, Nakamura H, Chida K, Kasamatsu N, Hayakawa H, Yasuda K, Saganuma H, Genma H, Tamura R, Shirai T, Shindoh J, Sato S, Taguchi O, Sasaki Y, Ibata H, Yasui M, Nakano Y, Ito M, Kitada S, Kimura H, **Inoue Y**, Yasuba H, Mochizuki Y, Horikawa S, Suzuki Y, Katakami N, Tanimoto Y, Hitsuda Y, Burioka N, Sato T, Kohno N, Yokoyama A, Nishioka Y, Ueda N, Kuwano K, Watanabe K, Aizawa H, Kohno S, Mukae H, Kohrogi K, Kadota J, Tokimatsu I, Miyazaki E, Sasaki T, Kawabata M. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. *Respir Res*. 12:93, 2011.
199. Okada M, Kita Y, Kanamaru N, Hashimoto S, Uchiyama Y, Mihara M, **Inoue Y**, Ohsugi Y, Kishimoto T, Sakatani M. Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF- α

- antibody in mice. *Clin Dev Immunol*. 2011;2011:404929. Epub 2011 Feb 22.
200. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, **Inoue Y**, Matsumoto M, McMurray DN, De la Cruz EC, Tan EV, Abalos RM, Burgos JA, Saunderson P, Sakatani M. Novel therapeutic vaccine: Granulysin and new DNA vaccine against Tuberculosis. *Hum Vaccin*. 7:60-7, 2011
201. **Inoue Y**. APSR Respiratory update, *APSR education publication* 3(5), Jun. 2011
202. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, **Inoue Y**, McMurray DN, Sakatani M. Novel Prophylactic Vaccine Using a Prime-Boost Method and Hemagglutinating Virus of Japan-Envelope against Tuberculosis. *Clin Dev Immunol*. 2011;2011:549281. Epub 2011 Mar 7.
203. Trapnell BC, Nakata K, **Inoue Y**. Autoimmune pulmonary alveolar proteinosis. *Molecular Basis of Pulmonary Disease Insights from Rare Lung Disorders*. p.111-132. Humana Press, Springer New York Dordrecht Heidelberg London. Edited by Francis X. McCormack, MD, Ralph J. Panos, MD, Bruce C. Trapnell, MD, 2010
204. Tazawa R, Trapnell BC, **Inoue Y**, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Eda R, Tsuchihashi Y, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. *Am J Respir Crit Care Med*. 181:1345-54, 2010
205. McCormack FX, Sullivan EJ, **Inoue Y**. Lymphangioleiomyomatosis. *Murray&Nadel's textbook of respiratory medicine*. Saunders Elsevier p. 1496-1515, (Mason RJ, Broaddus VC, Martin TR, et al.Ed.), 2010
206. Young LR, Vandyke R, Gulleman PM, **Inoue Y**, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis from Other Diseases. *Chest*. 2010 Sep;138(3):674-81
207. Nurok M, Eslick I, Carvalho CR, Costabel U, D'Armiento J, Glanville AR, Harari S, Henske EP, **Inoue Y**, Johnson SR, Lacronique J, Lazor R, Moss J, Ruoss SJ, Ryu JH, Seyama K, Watz H, Xu KF, Hohmann EL, Moss F. International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform. *Lymphat Res Biol*. 8(1) 81-87,2010
208. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Collaborators (77) Betsuyaku T, Sugawara Y, Fujiuchi S, Yamauchi K, Konishi K, Munakata M, Kimura Y, Ishii Y, Sugiyama Y, Kudoh K, Saito T, Yamaguchi T, Mizoo A, Nagai A, Ishizaka A, Yamaguchi K, Yoshimura K, Oritsu M, Fukuchi Y, Takahashi K, Kimura K, Yoshizawa Y, Nagase T, Hisada T, Ohta K, Yoshimori K, Miyazawa Y, Tatsumi K, Sasaki Y, Taniguchi M, Sugita Y, Suzuki E, Saito Y, Nakamura H, Chida K, Kasamatsu N, Hayakawa H, Yasuda K, Suganuma H, Genma H, Tamura R, Shirai T, Shindoh J, Sato S, Taguchi O, Sasaki Y, Ibata H, Yasui M, Nakano Y, Ito M, Kitada S, Kimura H, **Inoue Y**, Yasuba H, Mochizuki Y, Horikawa S, Suzuki Y, Katakami N, Tanimoto Y, Hitsuda Y, Burioka N, Sato T, Kohno N, Yokoyama A, Nishioka Y, Ueda N, Kuwano K, Watanabe K, Aizawa H, Kohno S, Mukae H, Kohrogi H, Kadota J, Tokimatsu I, Miyazaki E, Sasaki T, Kawabata M. Pirfenidone in idiopathic pulmonary fibrosis. *Eur Respir J*. 35(4):821-9, 2010
209. Ishii H, Trapnell BC, **Inoue Y**, et al. Comparative study of high-resolution ct findings between autoimmune

- and secondary pulmonary alveolar proteinosis. *Chest*.136(5):1348-55, 2009
210. Akira M, **Inoue Y**, Kitaichi M, Yamamoto S, Arai T, Toyokawa K. Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings. *Radiology*. 251: 271-9, 2009.
211. Akira M, Toyokawa K, **Inoue Y**, Arai T. Quatitative CT in chronic obstructive pulmonary disease: Inspiratory and expiratory assessment. *AJR*, 192:267-72, 2009
212. Shojima J, Tanaka G, **Inoue Y**, et al. Identification of MICA as a susceptibility gene for pulmonary Mycobacterium avium complex infection. *J Infect Dis*. 199(11): 1707-15, 2009
213. Okada M, Kita Y, **Inoue Y**, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. *Vaccine*. 27(25-26):3267-70, 2009
214. **Inoue Y**, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. *Am J Respir Crit Care Med*. 177:752-62, 2008
215. Young L, **Inoue Y**, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. *N Engl J Med*. 358:199-200, 2008
216. Arai T, **Inoue Y**, Eishi Y, et.al. Propionibacterium acnes in granulomas of a patient with necrotising sarcoid granulomatosis. *Thorax*. 63: 90-91, 2008
217. Hayashida M, Seyama K, **Inoue Y**, et.al. The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting featuresAnd prognostic factors. *Respirology* 12:523-30,2007
218. Hirata K, Sugame Y, **Inoue Y**, et.al. Enhanced mast cell chymase expression in human Idiopathic interstitial pneumonia. *Int J Mol Med*. 19:565-70, 2007
219. Mai HN, Hijikata M, **Inoue Y**, et.al.. Pulmonary MycobacteriumAvium complex infectionAssociated with the IVS8-T5Allele of the CFTRGene. *Int J Tuberc Lung Dis*. 11:808-13, 2007
220. Huqun, Izumi S, **Inoue Y**, et.al. Mutations in type IIb sodium phosphate co-transporter (SLC34A2) cause pulmonaryAlveolar microlithiasis. *Am J Respir Crit Care Med*. 175: 263-268. 2007.
221. Sugama Y, Ikura Y, **Inoue Y**, et. al.. Enhanced expression of angiotensin II type 1 receptor in usual interstitial pneumonia. *Osaka City Med J*. 53:87-95, 2007.
222. Arai T, **Inoue Y**, Eishi Y, Yamamoto S, Sakatani M. Propionibacterium acnes in granulomas of a patient with necrotising Sarcoid granulomatosis. *Thorax*. 63: 90-91, 2008
223. Young LR, **Inoue Y**, McCormack FX. Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis. *N Engl J Med*. 358: 199-200, 2008
224. **Inoue Y**, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Edac R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K, the Japanese Center of the Rare Lung Diseases Consortium. Characteristics of a Large Cohort of Autoimmune Pulmonary Alveolar Proteinosis Patients in Japan *Am J Respir Crit Care Med*. 177: 752–762, 2008
225. Hayashida M, Seyama K, **Inoue Y**, Fujimoto 1K, Kubo K. Respiratotory failure research group of the Japanese ministry of health, labour, and welfare. The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and Prognostic factors. *Respirology* , 12: 523-530, 2007.
226. Hirata K, Sugame Y, Ikura Y, Ohsawa M, **Inoue Y**, Yamamoto S, Kitaichi M, Ueda M. Enhanced mast cell

- chymase expression in human Idiopathic interstitial pneumonia. *Int J Mol Med.* 19: 565-570, 2007.
227. Mai HN, Hijikata M, **Inoue Y**, Suzuki K, Sakatani M, Okada M, Kimura K, Kobayashi N, Toyota E, Kudo K, Nagai H, Kurashima A, Kajiki A, Oketani N, Hayakawa H, Tanaka G, Shojima J, Matsushit I, Sakurada S, Tokunaga K, Keicho N. Pulmonary Mycobacterium avium complex infection associated with the IVS8-T5 allele of the CFTR gene. *Int J Tuberc Lung Dis.* 11: 808-813, 2007
228. Huqun, Izumi S, Miyazawa H, Ishii K, Uchiyama B, Ishida T, Tanaka S, Tazawa R, Fukuyama S, Tanaka T, Nagai Y, Yokote A, Takahashi H, Fukushima T, Kobayashi K, Chiba H, Nagata M, Sakamoto S, Nakata K, Takebayashi Y, Shimizu Y, Kaneko K, Shimizu M, Kanazawa M, Abe S, **Inoue Y**, Yoshimura K, Takenoshita S, Kudo K, Tachibana T, Nukiwa T, Hagiwara K. Mutations in type IIb sodium phosphate co-transporter (SLC34A2) cause pulmonary alveolar microlithiasis. *Am J Respir Crit Care Med.* 175: 263-268. 2007.
229. Sugama Y, Ikura Y, Yoshimi N, Suekane T, Kitabayashi C, Nakagawa M, Ohsawa M, Kitaichi M, Yamamoto S, **Inoue Y**, Hirata K, Ueda M. Enhanced expression of angiotensin II type 1 receptor in usual interstitial pneumonia. *Osaka City Med J.* 53(2):87-95. 2007
230. **Inoue Y**, Nakata K, Arai T, Tazawa R, Hamano E, Nukiwa T, Nakata K, Keicho N, Hizawa N, Yamaguchi E, Eda R, Oishi K, Maeda Y, Koreeda Y, Kodo N, Sakatani M. Epidemiological and clinical feature of idiopathic pulmonary alveolar proteinosis in Japan.. *Respirplogy* 11: S55-60, 2006
231. Tazawa R, Nakata K, **Inoue Y**, Nukiwa T. Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-macrophage colony-stimulating factor: a case report. *Respirology.* 11: S61-4, 2006
232. Ando S, Arai T, **Inoue Y**, Kitaichi M, Sakatani M. NSIP in a curry sauce factory worker. *Thorax.* 61:1012-1013, 2006
233. Arai T, **Inoue Y**, Hayashi S, Akira M, Yamamoto S, Travis WD, Sakatani M. Intractable desquamative interstitial pneumonia in a tattooed man. *Intern Med.* 45:1055-8, 2006
234. Wasfi Y, Rose C, James R. Murphy, Silveira LJ, Luna BL, Grutters JC, **Inoue Y**, Judson MA, Maier LA. A New Tool to Assess Sarcoidosis Disease Severity. *Chest*, 129:1234-45, 2006
235. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, Hashimoto S, **Inoue Y**, Sakatani M, Kobayashi E, Kaneda Y, Okada M : DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. *Vaccine*, 24:1191-1204, 2006
236. Tazawa R, Hamano E, Arai T, Ohta I H, Ishimoto O, Uchida K, Watanabe M, Saito J, Takeshita M, Hirabayashi Y, Ishige I, Eishi Y, Hagiwara K, Ebina M, **Inoue Y**, Nakata K, Nukiwa T. Granulocyte-macrophage colony stimulating factor and lung immunity in pulmonary alveolar proteinosis. . *Am J Resp Crit Care Med* 171:1142-9, 2005
237. Akira M, Kozuka T, **Inoue Y**, Sakatani M. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. *Chest.* 2005 Jan;127:185-91.
238. N.Yoshimi, Y.Ikura, Y.Sugama, S.Kayo, M.Ohsawa, S.Yamamoto, **Y.Inoue**, K.Hirata, H.Itabe, J.Yoshikawa, and M.Ueda. Oxidized Phosphatidylcholine in AlveolarMacrophages in Idiopathic Interstitial Pneumonias. *Lung.* 2005, 183(2):109-21.
239. T Arai, **Y Inoue**, S Hayashi, S Yamamoto and M Sakatani. Risedronate induced BOOP complicated with sarcoidosis. *Thorax* 60: 613-614, 2005.

240. Arai T, Inoue Y, Yamamoto S, Akira M, Uesugi H, Hayashi S, Sakatani M. Incipient stage of pulmonary Langerhans'-cell histiocytosis complicated with pulmonary tuberculosis happened to be examined by high resolution computed tomography. *Respiratory Medicine* 60;613-614, 2005
241. Y Miyake, S Sasaki, T Yokoyama, K Chida, A Azuma, T Suda, S Kudoh, N Samamoto, K Okamoto, G Kobashi, M Washio, Y Inaba, H Tanaka And The Japan Idiopathic Pulmonary Fibrosis Group (YInoue, M Sakatani). Case-control study of medical history and idiopathic pulmonary fibrosis in Japan. *Respirology*. 10: 504-509, 2005.
242. Yoshimi, Ikura N, Sugama Y, Kayo S, Ohsawa M, Yamamoto S, Inoue Y, Hirata K, Itabe H, Yoshikawa J, and Ueda M. Oxidized Phosphatidylcholine in Alveolar Macrophages in Idiopathic Interstitial Pneumonias. *Lung*, 183 : p109-121. 2005
243. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, Muraki Y, Kanamaru N, Hashimoto S, Takai H, Okada C, Fukunaga Y, Sakaguchi Y, Furukawa I, Yamada K, Inoue Y, Takemoto Y, Naito M, Yamada T, Matsumoto M, McMurray DN, Cruz EC, Tan EV, Abalos RM, Burgos JA, Gelber R, Skeiky Y, Reed S, Sakatani M, Okada M. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. *Vaccine*. 23:2132-5, 2005
244. Arai T, Hamano E, Inoue Y, Tazawa R, Nukiwa T, Sakatani M, Nakata K. Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. *Respiratory medicine*. 98: 1227-1230, 2004
245. Presneil I JJ, Nakata K, Inoue Y, Seymour JF. Alveolar proteinosis. *Clinics in Chest Med*. 25:593-613, 2004
246. Hayashi S, Abe K, Matsuoka H, Goya S, Morishita H, Mori M, Arai T, Kida H, Nishino K, Takeda Y, Osaki T, Tachibana I, Kimura K, Yokota S, Inoue Y, Sakatani M. Increased Level of Soluble E-Selectin in the Serum from Patients with Idiopathic Pulmonary Fibrosis. *Inflammation*, 28 : 1-5, 2004
247. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, Suzuki K, Inoue Y, Tsuyuguchi K, Sasaki Y, Mazurek GH, and Tsuyuguchi I. Specific Detection of Tuberculosis Infection an Interferon-gamma Based Assay using New Antigens. *Am J Crit Care Med*, 170: 59-64, 2004
248. Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. *Br J Cancer*. 88:887-94, 2003.
249. Akira M, Yamamoto S, Inoue Y, Sakatani M. High resolution computed tomographyc findings in asbestosis and idiopathic pulmonary fibrosis: a compareative study. *AJR*. 181: 163-169, 2003
250. Inoue Y, King TE Jr.,Barker E, Daniloff E, Newman LS. Basic Fibroblast Growth Factor and Its Receptors in Idiopathic Pulmonary Fibrosis and Lymphangioleimyomatosis. *Am J Resp Crit Care Med* 166: 765-773, 2002.
251. Okada M, Tanaka T, Inoue Y, Matsumoto K, Kita Y, Kimura K, Yoshida S, Ohara N, Naito M, Yamada T, Kaneda Y, Matsumoto M, Matsumoto S, Skeiky Y, Reed S, Sakatani M Novel (recombinant BCG- and DNA-) vaccination against tuberculosis. *Thirty-Seventh Tuberculosis and Leprosy Research Conference* 171-175, 2002
252. American Thoracic Society/European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (as a

- panel reviewer). *Am. J. Respir. Crit. Care Med* 165: 277-304, 2002
253. Inoue K, **Inoue Y**, Arai T, Nawa Y, Kashiwa Y, Yamamoto S, Sakatani M. Chronic eosinophilic pneumonia due to visceral larva migrans. *Internal Medicine*, 41: 478-482, 2002.
254. Ueno K, **Inoue Y**, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. *Lung Cancer*, 31: 213-219, 2001.
255. Okada M, Tanaka T, **Inoue Y**, Yoshida S, Ohara N, Yamada T, Matsumoto M, Sakatani M and Mori T: New (DNA- Recombinant BCG- and Subunit-) Vaccination against tuberculosis and cytotoxic activity. *Thirty-Sixth Tuberculosis and Leprosy Research Conference*. 127-133, 2001
256. Okada M, Yoshida S, Ohara N, Yamada T, Kaneda Y, Tanaka T, Kita Y, Kuwayama S, Muraki Y, Kanamaru N, Fukuda N, **Inoue Y**, Matsumoto M, Sakatani M, Mori T: Novel DNA and Recombinant BCG Vaccinations against Tuberculosis by the Augmentation of Cytotoxic Activity. *The Awaji International Forum on Infection and Immunity*. 049, 2001
257. Okada M, Yoshida S, Ohara N, Yamada T, **Inoue Y**, Minamoto S, Sakatani M, Mori T: DNA and recombinant BCG vaccination against tuberculosis by the augmentation of cytotoxic activity. *FASEB Journal*, A1008, 2001
258. Hamada H, Vallyathan V, Cool CD, Barker E, **Inoue Y**, Newman LS : Mast Cell Basic Fibroblast Growth Factor in Silicosis. *Am J Respir Crit Care Med*. 161: 2026-2034, 2000
259. Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, **Inoue Y**, Yamanaka H, Matsumura A, Iuchi K, Mori T, Okada M. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. *Int. J. Cancer (Pred. Oncol.)* 89: 488-493, 2000
260. Akira M, **Inoue Y**, Yamamoto S, Sakatani M. Non-specific interstitial pneumonia : findings on sequential CT scans of nine patients. *Thorax*. 55(10): 854-859, 2000
261. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, Hanaoka K, Seymour JF, Schoch OD, Doyle I, **Inoue Y**, Sakatani M, Kudoh S, Azuma A, Nukiwa T, Kanegasaki S, Nakata K. Serological Diagnosis of Idiopathic Pulmonary Alveolar Proteinosis. *Am J Respir Crit Care Med*. 2000, 162: 658-662
262. **Inoue Y**, Kawaguchi T, Yoshida A, Harada H, Hara H, Yamamoto S, Sakatani M. Paragonimiasis Miyazakii Associated with Bilateral Pseudochylothorax. *Internal Medicine*. 39(7): 579-582, 2000
263. Okada M, Tanaka T., **Inoue Y**, Katayama Y., Yoshida S., Ohara N., Yamada T., Kayagaki N., Yagita H., Okumura K. Sakatani M. and Mori T.: DNA and recombinant BCG vaccination against tuberculosis and cytotoxic activity in the patients with multi-drug resistant tuberculosis. *Thirty-Fifth research conference on tuberculosis and leprosy*, p.197-201, 2000
264. Kawaguchi T, Matumura A, Iuchi K, Yamamoto S, **Inoue Y**, Sunami T, Naka N, Okishio K, Ueno K, Atagi S, Ogawara M, Hosoe S, Kawahara M, Solitary squamous papilloma of the bronchus associated with human papilloma virus type II. *Internal Medicine*, 38: 817-819, 1999.
265. Uh ST, **Inoue Y**, King TE Jr, Chan ED, Newman LS, Riches DWH. Morphometric analysis of insulin-like growth factor-I localization in lung tissue of patients with idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med*. 158: 1626-1635, 1998
266. **Inoue Y**, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary Epithelial Cell Injury and Alveolar-Capillary Permeability in Berylliosis. *Am J Resp Crit Care Med*.156:109-115, 1997 .

267. Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. *Am J Respir Cell Mol Biol.* 17:501-507, 1997
268. Inoue Y, King TE Jr, Tinkle SS, Dockstader K, Newman LS. Human mast cell basic fibroblast growth factor in fibrotic pulmonary disorders. *Am J Pathol* 149: 2037-2054, 1996
269. Inoue Y, Daniloff CM, Daniloff E, Lloid J, Tinkle S, King TE Jr. Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. *Chest*, 109(3):43S-44S, 1996
270. Kouki Watanabe, Kazutaka Nishimura, Masahiro Shiode, M Sekiya, Shuntaro Ikeda, Yoshikazu Inoue, C Iwanaga. Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. *Internal Medicine* 35:142-145, 1996
271. Yoshikazu Inoue, Kazutaka Nishimura, Masahiro Shiode, Hiroshi Akutsu, Hironobu Hamada, Seiji Fujioka, Shun Fujino, Akihito Yokoyama, Nobuoki Kohno, Kunio Hiwada: Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. *Tubercle and Lung Diseases* 76: 230-233, 1995
272. Taishi Kuwahara, Mareomi Hamada, Yoshikazu Inoue, Shuji Aono, Kunio Hiwada: Warfarin-induced eosinophilic pleurisy. *Internal Medicine* 34: 794-796, 1995
273. Akihito Yokoyama, Nobuoki Kohno, Shun Fujino, Yoshikazu Inoue, Kunio Hiwada: IgG and IgM rheumatoid factor levels parallel interleukin-6 during the vasculitic phase in a patients with Churg-Strauss syndrome. *Internal Medicine* 34: 646-648, 1995
274. Akihito Yokoyama, Nobuoki Kohno, Yutaka Hirasawa, Kenichi Kondo, Masahiro Abe, Yoshikazu Inoue, Seiji Fujioka, Shun Fujino, Satoshi Ishida, Kunio Hiwada: Evaluation of soluble interleukin-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. *Clin Eep Immunol* 100: 325-329, 1995
275. Akihito Yokoyama, Nobuo Kohno, Shun Fujino, Hironobu Hamada, Yoshikazu Inoue, Seiji Fujioka, Satoshi Ishida, Kunio Hiwada. Circulating interleukin-6 levels in patients with bronchial asthma. *Am J Respir Crit Care Med* 151:1354-1358, 1995
276. Osamu Sasaki, Akihito Yokoyama, Shigeki Uemura, Shun Fujino, Yoshikazu Inoue, Nobuoki Kohno, Kunio Hiwada. Drug eruption caused by recombinant human G-CSF. *Internal Medicine* 33:641-643, 1994
277. Nobuoki Kohno, Yoshikazu Inoue, Hironobu Hamada, Seiji Fujioka, Shun Fujino, Akihito Yokoyama, Kunio Hiwada, N Ueda, Mitoshi Akiyama. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. *Int J Cancer* s8: 81-83, 1994
278. Akihito Yokoyama, Nobuyuki Kohno, Shun Fujino, Hironobu Hamada, Yoshikazu Inoue, Seiji Fujioka, Kunio Hiwada. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. *Oncology Reports* 1:507-511, 1994
279. Nobuoki Kohno, Yukikazu Awaya, Tetsu Oyama, Michio Yamakido, Mitoshi Akiyama, Yoshikazu Inoue, Akihito Yokoyama, Hironobu Hamada, Seiji Fujioka, Kunio Hiwada. KL-6, a mucin-like glycoprotein in brochoalveolar lavage fluids from patients with interstitial lung diseases. *Am Rev Respir Dis* 148:637-642, 1993.
280. Kenichi Kondo, Yoshikazu Inoue, Hironobu Hamada, Akihito Yokoyama, Nobuoki Kohno, Kunio Hiwada. Acetaminophen-induced eosinophilic pneumonia. *Chest* 104: 291-292, 1993
281. Nobuoki Kohno, Masayuki Miyake, Yoshikazu Inoue, Akihito Yokoyama, Kunio Hiwada, Masaru Tanabe,

- Michio Yamakido, Seishi Kyoizumi, Mitoshi Akiyama. A circulating heat-resistant mucin-like antigen in patients with lung cancer detected by a new murine monoclonal antibody. *Internal J Oncology* 1:649-655, 1992
282. Kunio Hiwada, **Yoshikazu Inoue**, Tatsuo Kokubu. Effect of SQ29,852, a new angiotensin converting enzyme (ACE) inhibitor with a phosphanic acid group, on the activity of angiotensin converting enzyme from human kidney. *Gen Pharmac* 21:555-558, 1990
283. Yasuharu Takada, Yutaka Kitami, **Yoshikazu Inoue**, Kunio Hiwada, Tatsuo Kokubu. Immunohistologic characterization of angiotensin converting enzyme in the human kidney using monoclonal and polyclonal antibodies. *Adv Exp Med Biol* 247A:175-180, 1989
284. **Yoshikazu Inoue**, Akihito Hashimoto, Kunio Hiwada, Tatsuo Kokubu. Measurement of angiotensin-converting enzyme in bronchoalveolar lavage fluid by radioimmunoassay. *Clin Chem Enzym Comms* 2:43-47, 1989
285. Kunio Hiwada, **Yoshikazu Inoue**, Yasuharu Takada, Akihito Hashimoto, Hiroshi Akutsu, F Kitatani, Tatsuo Kokubu. Direct radioimmunoassay of angiotensin-converting enzyme in sera from patients with pulmonary diseases. *Lung* 165:27-35, 1987
286. Kazutaka Nishimura, **Yoshikazu Inoue**, Tatsuo Kokubu. Radioimmunoassay of glandular kallikrein in human plasma after partial purification by immunoaffinity column. *Clin Chim Acta* 1987, 162:341-347.
287. **Yoshikazu Inoue**, Akihito Hashimoto, Yasuharu Takada, Kazutaka Nishimura, Kunio Hiwada, Tatsuo Kokubu. Angiotensin converting enzyme in sarcoidosis and silicosis. *Clin Exp Hypertens* A9(2-3): 481-485, 1987